Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape
Curr Oncol. 2024 Apr 3;31(4):1971-1993. doi: 10.3390/curroncol31040148.ABSTRACTMyelodysplastic neoplasms (MDS) are a heterogenous clonal disorder of hemopoietic stem cells characterized by cytomorphologic dysplasia, ineffective hematopoiesis, peripheral cytopenias and risk of progression to acute myeloid leukemia (AML). Our understanding of this disease has continued to evolve over the last century. More recently, prognostication and treatment have been determined by cytogenetic and molecular data. Specific genetic abnormalities, such as deletion of the long arm of chromosome 5 (del(5q)), TP53 inactivation and SF3B1 mutati...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Daniel Karel Claire Valburg Navitha Woddor Victor E Nava Anita Aggarwal Source Type: research
The DNA damage-independent ATM signalling maintains CBP/DOT1L axis in MLL rearranged acute myeloid leukaemia
Oncogene, Published online: 26 April 2024; doi:10.1038/s41388-024-02998-2The DNA damage-independent ATM signalling maintains CBP/DOT1L axis in MLL rearranged acute myeloid leukaemia (Source: Oncogene)
Source: Oncogene - April 26, 2024 Category: Cancer & Oncology Authors: Guangming Wang Wenjun Zhang Jie Ren Yu Zeng Xiuyong Dang Xiaoxue Tian Wenlei Yu Zheng Li Yuting Ma Pingping Yang Jinyuan Lu Junke Zheng Bing Lu Jun Xu Aibin Liang Source Type: research
Revisiting the role of measurable residual disease in FLT3 mutated acute myelogenous leukemia
Expert Rev Hematol. 2024 Apr 23. doi: 10.1080/17474086.2024.2347303. Online ahead of print.NO ABSTRACTPMID:38654593 | DOI:10.1080/17474086.2024.2347303 (Source: Expert Review of Hematology)
Source: Expert Review of Hematology - April 24, 2024 Category: Hematology Authors: H åkon Reikvam Richard Dillon Source Type: research
Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens
Haematologica. 2024 Apr 24. doi: 10.3324/haematol.2024.285225. Online ahead of print.ABSTRACTIn newly diagnosed acute myeloid leukemia, immediate initiation of treatment is standard of care. However, deferral of antileukemic therapy may be indicated to assess comorbidities or pre-therapeutic risk factors. We explored the impact of time from diagnosis to treatment on outcomes in newly diagnosed acute myeloid leukemia undergoing venetoclax-based therapy in two distinct cohorts. By querying the Study Alliance Leukemia database and the global health network TriNetX, we identified 138 and 717 patients respectively with an avera...
Source: Haematologica - April 24, 2024 Category: Hematology Authors: David Baden Sven Zukunft Gema Hernandez Nadine Wolgast Sophie Steinhauser Alexander Pohlmann Christoph Schliemann Jan-Henrik Mikesch Bjorn Steffen Tim Sauer Maher Hanoun Kerstin Schafer-Eckart Stefan W Krause Mathias Hanel Hermann Einsele Edgar Jost Tim H Source Type: research
Pediatric acute promyelocytic leukemia and Fanconi anemia: Case report and literature review
We report a 4 year-old boy from non-consanguineous parents diagnosed with standard risk APL. This child had café-au-lait spots and an extra thumb remnant. Genomic sequencing revealed two PV in FANCD1/BRCA2 confirming a diagnosis of FA-D1. Chromosomal breakage studies were compatible with FA. Each parent carried one variant and had no personal history of cancer. Morphological then molecular remissions were achieved with all-trans retinoic acid and Arsenic trioxide. This patient underwent haploidentical stem cell transplant. In addition to our patient, a literature search revealed four additional patients with APL/FA, with ...
Source: Clinical Genetics - April 24, 2024 Category: Genetics & Stem Cells Authors: Claire Freycon Edith Sepulchre Vincent-Philippe Lavall ée David Mitchell Margaret L MacMillan Catherine Vezina Catherine Goudie Source Type: research
Revisiting the role of measurable residual disease in FLT3 mutated acute myelogenous leukemia
Expert Rev Hematol. 2024 Apr 23. doi: 10.1080/17474086.2024.2347303. Online ahead of print.NO ABSTRACTPMID:38654593 | DOI:10.1080/17474086.2024.2347303 (Source: Expert Review of Hematology)
Source: Expert Review of Hematology - April 24, 2024 Category: Hematology Authors: H åkon Reikvam Richard Dillon Source Type: research
GSE239307 Inflammatory conversion of normal hematopoietic stem and progenitor cells by acute myeloid leukemia derived extracellular vesicles in vivo
Contributors : Ding-Wen Chen ; Julie M Schrey ; Jian-Meng Fan ; Dana V Mitchell ; Deanne M Taylor ; Peter KurreSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusInflammation in the bone marrow (BM) microenvironment is a constitutive component of acute myeloid leukemia (AML) pathogenesis. Studies have demonstrated that leukemic blasts propagate acute inflammation in the AML niche. Our recent studies in a congenic AML model suggest residual healthy hematopoietic stem and progenitor cells (HSPCs) participate in the inflammatory crosstalk. However, the underlying mechanism that drives th...
Source: GEO: Gene Expression Omnibus - April 24, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Mus musculus Source Type: research
Role of the STING pathway in myeloid neoplasms: a prospero-registered systematic review of principal hurdles of STING on the road to the clinical practice
AbstractMyeloid neoplasms are a group of bone marrow diseases distinguished by disruptions in the molecular pathways that regulate the balance between hematopoietic stem cell (HSC) self-renewal and the generation of specialized cells. Cytokines and chemokines, two important components of the inflammatory process, also influence hematological differentiation. In this scenario, immunological dysregulation plays a pivotal role in the pathogenesis of bone marrow neoplasms. The STING pathway recognizes DNA fragments in the cell cytoplasm and triggers an immune response by type I interferons. The role of STING in cancer has not ...
Source: Medical Oncology - April 24, 2024 Category: Cancer & Oncology Source Type: research
FLT3 agonists and secondary hematopoietic malignancies: a potential class effect
Clin Cancer Res. 2024 Apr 23. doi: 10.1158/1078-0432.CCR-24-0460. Online ahead of print.ABSTRACTExpansion of cDC cells via FLT3 agonism has promising therapeutic potential in the treatment of advanced solid tumors. Here, we discuss the results of a clinical trial using GS-3583, an FLT3 agonist, that was stopped after a patient in the study developed acute myeloid leukemia.PMID:38652676 | DOI:10.1158/1078-0432.CCR-24-0460 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 23, 2024 Category: Cancer & Oncology Authors: Henry W Raeder Michael W Drazer Source Type: research
Bortezomib suppresses acute myelogenous leukaemia stem-like KG-1a cells via NF- κB inhibition and the induction of oxidative stress
J Cell Mol Med. 2024 Apr;28(8):e18333. doi: 10.1111/jcmm.18333.ABSTRACTAcute myelogenous leukaemia (AML) originates and is maintained by leukaemic stem cells (LSCs) that are inherently resistant to antiproliferative therapies, indicating that a critical strategy for overcoming chemoresistance in AML therapy is to eradicate LSCs. In this work, we investigated the anti-AML activity of bortezomib (BTZ), emphasizing its anti-LSC potential, using KG-1a cells, an AML cell line with stem-like properties. BTZ presented potent cytotoxicity to both solid and haematological malignancy cells and reduced the stem-like features of KG-1a...
Source: J Cell Mol Med - April 23, 2024 Category: Molecular Biology Authors: Rafaela G A Costa Maiara de S Oliveira Ana Carolina B da C Rodrigues Suellen L R Silva Ingrid R S B Dias Milena B P Soares Ludmila de Faro Valverde Clarissa Araujo Gurgel Rocha Rosane Borges Dias Daniel P Bezerra Source Type: research
Bortezomib suppresses acute myelogenous leukaemia stem-like KG-1a cells via NF- κB inhibition and the induction of oxidative stress
J Cell Mol Med. 2024 Apr;28(8):e18333. doi: 10.1111/jcmm.18333.ABSTRACTAcute myelogenous leukaemia (AML) originates and is maintained by leukaemic stem cells (LSCs) that are inherently resistant to antiproliferative therapies, indicating that a critical strategy for overcoming chemoresistance in AML therapy is to eradicate LSCs. In this work, we investigated the anti-AML activity of bortezomib (BTZ), emphasizing its anti-LSC potential, using KG-1a cells, an AML cell line with stem-like properties. BTZ presented potent cytotoxicity to both solid and haematological malignancy cells and reduced the stem-like features of KG-1a...
Source: Molecular Medicine - April 23, 2024 Category: Molecular Biology Authors: Rafaela G A Costa Maiara de S Oliveira Ana Carolina B da C Rodrigues Suellen L R Silva Ingrid R S B Dias Milena B P Soares Ludmila de Faro Valverde Clarissa Araujo Gurgel Rocha Rosane Borges Dias Daniel P Bezerra Source Type: research
FLT3 agonists and secondary hematopoietic malignancies: a potential class effect
Clin Cancer Res. 2024 Apr 23. doi: 10.1158/1078-0432.CCR-24-0460. Online ahead of print.ABSTRACTExpansion of cDC cells via FLT3 agonism has promising therapeutic potential in the treatment of advanced solid tumors. Here, we discuss the results of a clinical trial using GS-3583, an FLT3 agonist, that was stopped after a patient in the study developed acute myeloid leukemia.PMID:38652676 | DOI:10.1158/1078-0432.CCR-24-0460 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 23, 2024 Category: Cancer & Oncology Authors: Henry W Raeder Michael W Drazer Source Type: research
GSE239350 Identifying STRN3-RARA as a new fusion gene for acute promyelocytic leukemia [RNA-seq 2]
Contributors : Xuelan Chen ; Qi Zhang ; Chong Chen ; Yu LiuSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiens ; Mus musculusAcute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia, that is generally driven by PML-RARA, resulting from a balanced chromosomal translocation t(15;17) (q24.1;q21.2). However, approximately 2% of APL patients carry other variants of RARA-fusions, which pose challenges for diagnosis and treatment. Here, we report a novel t(14;17) translocation in an APL patient that gave rise to a new fusion gene, STRN3-RARA. STRN3 forms a complex ...
Source: GEO: Gene Expression Omnibus - April 23, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Mus musculus Source Type: research
GSE224815 Identifying STRN3-RARA as a new fusion gene for acute promyelocytic leukemia [RNA-seq]
Contributors : Xuelan Chen ; Qi Zhang ; Chong Chen ; Yu LiuSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensAcute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia, that is generally driven by PML-RARA, resulting from a balanced chromosomal translocation t(15;17) (q24.1;q21.2). However, approximately 2% of APL patients carry other variants of RARA-fusions, which pose challenges for diagnosis and treatment. Here, we report a novel t(14;17) translocation in an APL patient that gave rise to a new fusion gene, STRN3-RARA. STRN3 forms a complex called the stri...
Source: GEO: Gene Expression Omnibus - April 23, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
GSE224813 Identifying STRN3-RARA as a new fusion gene for acute promyelocytic leukemia [CUT & TAG]
Contributors : Xuelan Chen ; Qi Zhang ; Chong Chen ; Yu LiuSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensAcute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia, that is generally driven by PML-RARA, resulting from a balanced chromosomal translocation t(15;17) (q24.1;q21.2). However, approximately 2% of APL patients carry other variants of RARA-fusions, which pose challenges for diagnosis and treatment. Here, we report a novel t(14;17) translocation in an APL patient that gave rise to a new fusion gene, STRN3-RARA. STRN3 forms a complex c...
Source: GEO: Gene Expression Omnibus - April 23, 2024 Category: Genetics & Stem Cells Tags: Genome binding/occupancy profiling by high throughput sequencing Homo sapiens Source Type: research
